Efficacy of neoadjuvant pembrolizumab combined with paclitaxel and cisplatin in locally advanced oropharyngeal and hypopharyngeal squamous cell carcinoma: a retrospective study.

Shupin Tang, Gongbiao Lin, Xiaobo Wu, Zhihong Chen

Abstract read

In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shupin Tang *Department of Otolaryngology Head and Neck Surgery, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Gongbiao Lin *Department of Otolaryngology Head and Neck Surgery, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Xiaobo WuDepartment of Otolaryngology Head and Neck Surgery, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Zhihong ChenDepartment of Otolaryngology Head and Neck Surgery, the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This retrospective study aims to evaluate the efficacy and safety of pembrolizumab combined with paclitaxel and cisplatin (ICI+TP) in the treatment of locally advanced oropharyngeal and hypopharyngeal squamous cell carcinoma (OPHSCC). Methods: Patients with locally advanced OPHSCC who received ICI+TP, cetuximab with paclitaxel-cisplatin (CET+TP), or paclitaxel-cisplatin alone (TP) were reviewed. Radiographic and pathological response rates, transoral surgery rates, and survival outcomes were assessed. Results: A total of 83 patients were enrolled in this study, with 23 subjected to ICI+TP, 31 to CET+TP, and 29 to TP. Compared with TP, ICI+TP yielded superior clinical outcomes: a higher objective response rate (ORR) (91.3% vs. 55.2%, Conclusion: In locally advanced OPHSCC, neoadjuvant pembrolizumab combined with paclitaxel and cisplatin showed a higher ORR and increased transoral surgery rates while preserving laryngeal function, with no increase in severe treatment-related adverse events, demonstrating favorable efficacy and safety profiles.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsHypopharyngeal NeoplasmsOropharyngeal NeoplasmsSquamous Cell Carcinoma of Head and NeckAdultAgedCisplatinFemaleHumansMaleMiddle AgedNeoadjuvant TherapyPaclitaxelRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedCisplatinPaclitaxelpembrolizumabchemoimmunotherapyimmune checkpoint inhibitorslocally advanced oropharyngeal and hypopharyngeal cancerneoadjuvant therapytransoral surgery

Identifiers

PMID41357220

DOI10.3389/fimmu.2025.1690935

PMCPMC12678248

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.